Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.
July 24, 2024
Dr. Ola Landgren shares insights on bispecific antibodies and quadruple therapy for multiple myeloma at the European Hematology Association
July 10, 2024
Four-drug combinations beat three-drug combinations for newly diagnosed myeloma patients, achieving higher MRD-negative rates regardless of fitness status.
June 24, 2024
BCMA-directed CAR T cell therapy significantly improves survival outcomes in relapsed myeloma patients compared to other therapies for R/R myeloma.
June 12, 2024
Learn about the IMROZ study's promising results combining Isa-VRd which improves remissions and response rates in newly diagnosed myeloma.
June 04, 2024
New data presented at ASCO 2024 of belantamab mafodotin (bela-maf or Blenrep) shows positive benefit for myeloma patients in two clinical trials.
May 27, 2024
The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…
March 28, 2024
As myeloma patients live longer, a new condition can be detected called clonal hematopoiesis that puts myeloma patients at higher risk for other blood cancers.
January 30, 2024
HealthTree Myeloma Editor, Audrey Burton-Bethke, shares her thoughts on the ASH session about clinical investigator perspectives on myeloma patient management.
What groundbreaking multiple myeloma news did we cover from the ASH 2023 conference this year? See a recap here.
January 18, 2024
How does real world data on a commonly used drug, bortezomib, affect newly diagnosed myeloma treatment today? An ASH study shares insight.
Understanding MGUS, Its Progression Risks, and More
Aug 15 / 13:00 EDT
Virtual Black Myeloma Health Movement Awareness Event 2024
Aug 17 / 0:00 EDT
Elranatamab: How it works, how it's being used, and how it compares to other bispecifics.
Aug 20 / 18:00 EDT